FABRY DISEASE: Phenotypic Spectrum Genotype/Phenotype Correlations Enzyme Replacement Therapy (ERT) R. J. Desnick, Ph.D., M.D.
|
|
- Clement Cooper
- 5 years ago
- Views:
Transcription
1 FABRY DISEASE: Phenotypic Spectrum Genotype/Phenotype Correlations Enzyme Replacement Therapy (ERT) R. J. Desnick, Ph.D., M.D. Director, International Center for Fabry Disease Dean for Genetic & Genomic Medicine Professor & Chair Emeritus Department of Genetics & Genomic Sciences Icahn School of Medicine at Mount Sinai, New York
2 FABRY DISEASE AN X-LINKED LYSOSOMAL STORAGE DISEASE α-galactosidase A Xq22.1 Human X Chromosome
3 FABRY DISEASE: X-LINKED INHERITANCE If Father Is Affected All Daughters Heterozygotes All Sons Unaffected If Mother Is Heterozygotes 50% Daughters Heterozygotes 50% Sons Unaffected
4 METABOLIC DEFECT IN FABRY DISEASE Globotriaosylceramide (GL-3, Gb3) Gal α β β Gal Glu Ceramide α-galactosidase A (α-gal A) Gal Gal Glu Ceramide Lactosylceramide (GL-2, Gb2)
5 PHENOTYPIC SPECTRUM OF FABRY DISEASE Affected Males Later-Onset Phenotypes: Cardiac Subtype Renal Subtype Classic Phenotype <1% Increasing α-gal A Activity >1% Classic Phenotype (Severe Disease) Later-Onset Phenotype Years
6 MAJOR EARLY SITES OF GL-3 ACCUMULATION Micro-Vascular Endothelium & Smooth Muscle: Ischemia & Occlusion: Acroparesthesias, Hypohidrosis, GI Pain, Angiokeratoma Cardiomyocytes: Early Diastolic Dysfunction > LVH & Mitral Insufficiency in Adolescents; Arrythmias Later Renal Endothelial,Podocytes & Tubular Cells: Microalbuminuria > Proteinuria; Isosthenuria, Sediment Inclusions
7 MANIFESTATIONS IN ADOLESCENTS & ADULTS Vascular Glycolipid Manifestations Deposition Skin Angiokeratoma Peripheral Nerves Acroparesthesias; Excruciating Pain Sweat Glands Hypohidrosis Intestine Abdominal Pain/Diarrhea Heart LVH, Myopathy, Arrythmias Brain TIAs, Strokes Kidney Renal Failure Average Age at Death ~40 Years
8 FABRY DISEASE: AGE AT DIALYSIS Thadhani et al., Kidney Int. 61:249, USRDS EDTA-ERA % Patie ents % Females 0 < Age (Years)
9 FABRY DISEASE: SURVIVAL ON DIALYSIS (USRSD ) Thadhani et al., Kid. Int. 61:249, 2002 Survival Distribution Function Non-DM Control Fabry Disease DM Control Time of Follow-Up (Years)
10 FABRY DISEASE: SURVIVAL AFTER RENAL TRANSPLANTATION Oto et al., Transplantation 69: , 2000 Fabry Disease (n = 93) Percent of Patie ents Alive Matched Control (n = 186) Months Post-Transplant
11 RENAL PATHOLOGY: STORAGE TO FIBROSIS Early Disease ESRD
12 KIDNEY DAMAGE STARTS IN FABRY CHILDREN EVEN BEFORE PROTEINURIA Gubler et al., Early Renal Changes in Hemizygous and Heterozygous Patients with Fabry Disease. Kidney Int 13: , 1978 Sheth et al., Early Renal Failure in Fabry s Disease. Am J Kidney Dis 2: , 1983 Tondel et al., Renal Biopsy Findings in Children and Adolescents with Fabry Disease and Minimal Albuminuria. Am J Kidney Dis 51: , 2008 Ramaswami et al., Assessment of Renal Pathology and Dysfunction In Children With Fabry Disease. Clin J Am Soc Nephrol 5: , 2010 Fogo et al., Scoring System for Renal Pathology in Fabry Disease: Report of the International Study Group of Fabry Nephropathy. Nephrol Dial Transplant 25: , 2010
13 KIDNEY DAMAGE STARTS IN FABRY CHILDREN EVEN BEFORE PROTEINURIA Najafian & Mauer, Quantitating Glomerular Endothelial Fenestration: An Unbiased Stereological Approach Am J Nephrol 33 (suppl 1):34-39, 2011 Najaflan et al., Progressive Podocyte Injury and GL-3 Accumulation in Young Patients with Fabry Disease Kidney Int 79: , 2011 Najafian et al., Renal Complications of Fabry Disease in Children. Pediatr Nephrol epub Aug 2012 Tondel et al., Agalsidase Benefits Renal Histology In Young Patients With Fabry Disease. J Am Soc Nephrol 24: , 2013
14 Naiafian et al., Pediatr Nephrol, Epub Aug 17, 2012 ELECTRON MICROGRAPH OF A GLOMERULUS FROM AN 11 YEAR OLD BOY WITH FABRY DISEASE The Patient Had Normal Glomerular Filtration Rate (GFR) and a Urine Protein/Creatinine Ratio of ~ 40 mg/g at Biopsy
15 PHENOTYPIC SPECTRUM OF FABRY DISEASE Later-Onset Phenotypes: Residual (>1%) α-gal A Activity; Missense Some Splicing Mutations; CRIM-Positive Most Lack Pain, Skin Lesions, Hypohidrosis, Eye Changes : Cardiac Subtype: No Vascular Endothelial GL-3 Accumulation Late-Onset: LVH, Myopathy, Arrhythmias, Proteinuria, Normal Renal Function for Age Renal Subtype:: Variable, but Late-Onset Renal Failure at 50-80s
16 RENAL PATHOLOGY Meehan et al., Am J Kidney Dis 43: , 2004 Classic Phenotype p.r227x 75 y/o Cardiac Later-Onset Phenotype p.n215s
17 ENZYMATIC DIAGNOSIS α-galactosidase A Activity Plasma Leukocytes α-gal Activity α-gal Activity
18 The New England Journal of Medicine 345: 9-16, 2001 Safety and Efficacy of Recombinant Human α-galactosidase A Replacement Therapy in Fabry Disease The International Fabry Disease Study Group Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldeck S, Caplan L, Linthorst GA, and Desnick RJ Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study: 8 Sites in 4 Countries 58 Classical Affected Patients: 56 M; 2 F Average Age: 30 yrs Dose: 1 mg/kg q 2 wk x11 Doses of Human α-gal A Produced in CHO Cells by Genzyme
19 % Zero-S Scores PRIMARY ENDPOINT RESULTS Renal Histology: Capillary Endothelium Clearance Double Blind P < (2x2 Chi Square) 20/29 69% 24/24 100% Extension Study 23/25 92% /29 0% Placebo Fabrazyme Week 20* PL / FZ FZ / FZ + 6 Months* *As Treated Population, Considered Equivalent to Intent-To-Treat
20 Am. J. Hum. Genet. 75:65-74, 2004 Long Term Safety and Efficacy of Enzyme Replacement Therapy for Fabry Disease Wilcox WR, Benikazemi M, Guffon N, Waldeck S, Lee P, Linthorst GA, Germain DP, and Desnick RJ The International Fabry Disease Study Group All 58 Patients from Phase 3 Continued in Extension Study Dose: 1 mg/kg q 2 wk of Fabrazyme After 30 to 36 Months of ERT: Sustained Capillary Endothelial GL-3 Clearance Plasma GL-3 Remained Normal Mean Serum Creatinine and Estimated GFR Remained Stable Infusion Associated Reactions Continued to Decreased with Time
21 J. Am. Soc. Nephrol., 18: , 2007 Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Beta Therapy in Patients with Fabry Disease Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wlicox WR, Guffon N. The International Fabry Disease Study Group
22 PHASE 4 CLINICAL TRIAL Ann Intern Med. 146:77-86, 2007 Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R,Packman S, Bichet DG, Warnock DG, and Desnick, RJ. Largest Randomized, Double-Blind, Placebo-Controlled Trial in Fabry Disease (n = 82) Narrow Inclusion Criteria: Mid to Moderate Renal Disease: Serum Creatinine 1.2 mg/dl to < 3.0 mg/dl Resulted in High Screening Failure (67&%) 252 Patients Screened at 41 Eligible Sites in 9 Countries
23 PRIMARY ENDPOINT - PROBABILITY OF AN EVENT Kaplan-Meier Analysis of Time to the First Occurrence of a Composite Event Risk Reduction 61% (p=0.034) Percen nt Placebo 44% Events 12/27 Patients Fabrazyme 28% Events 13/47 Patients Time in Study (Months)
24 SUMMARY: PHASE 4 CLINICAL TRIAL ERT IN ADVANCED DISEASE SLOWS CLINICAL PROGRESSION Fabrazyme Therapy Slowed the Rate of Clinical Progression as Manifested by Renal, Cardiac, and Cerebrovascular Outcomes in Patients with Advance Disease There was a 61% Risk Reduction for Events in Patients Treated with Fabrazyme (p = 0.034) Indicated Importance of Reducing Proteinuria with ACEi & ARBs Most Pronounced Effects Observed in Patients Who Had Less Advanced Disease, Emphasizing the Importance of Early Treatment
25 EFFECTS OF EARLY ERT & DOSE ON FABRY RENAL DISEASE & REVERSIBILITY Tøndel et al., J Am Soc Nephrol 24: , 2013 Compared α-gal A Dose & Cumulative Dose on Renal Biopsy Morphology Before & After 5 Yrs of ERT in 12 Patients (1F) from 7-33 Yrs (9<18 Yrs) 7 Patients on 0.2 mg/kg EOW, 2 on Varying Dose & 3 on 1 mg/kg EOW All Doses Cleared Glomerular Endothelial & Mesangial Cell Inclusions Podocyte GL-3 Clearance Was Highly Correlated with Cumulative Dose(p =0.002) There Was Essentially No GL3 Podocyte Clearance at 0.2 mg/kg EOW (7 Patients) Patients on 1 mg/kg EOW Cleared Podocyte & Tubular GL-3 Podocyte Clearance & Decreased Albumin/Creatinine Were Highly Correlated (p = ) The Current Study. Suggests Early Initiation of Treatment & the Use of Sufficiently High Enzyme Dose to Achieve Maximal Clearance of Kidney Cells
26 APPROVAL OF FABRAZYME FOR ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE Country Dose Date (mg/kg) European Union 1.0 August, 2001 United States 1.0 April, 2003 Approved in Over 50 Countries
Fabry disease: when to suspect it and how to treat it
Fabry disease: when to suspect it and how to treat it Catalina Martín Cleary Alberto Ortiz Arduán, MD, PhD IIS-Fundacion Jimenez Diaz, UAM IRSIN, REDINREN Madrid, Spain Conflict of interest Consultant:
More informationFabry Disease and the Kidneys
Department of Human Genetics Division of Medical Genetics Lysosomal Storage Disease Center www.genetics.emory.edu Fabry Disease and the Kidneys What is Fabry Disease? Fabry disease (FD) is an X-linked
More informationNatural History and Treatment of Renal Involvement in Fabry Disease
J Am Soc Nephrol 13: S139 S143, 2002 Natural History and Treatment of Renal Involvement in Fabry Disease MARY BRANTON,* RAPHAEL SCHIFFMANN, and JEFFREY B. KOPP* *Kidney Disease Section, National Institute
More informationThe use of pathology surrogate markers in Fabry Disease. Beth L. Thurberg MD PhD Vice President of Pathology Genzyme
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the EveryLife Foundation for Rare Diseases for educational purposes only. They are for use by drug development professionals
More informationClinical Appearance and Management of Fabry Nephropathy in Greece
BANTAO Journal 2010; 8 (2): 75-80 BJ BANTAO Journal Original article Clinical Appearance and Management of Fabry Nephropathy in Greece Andrikos K. Emilios 1, Iatrou E. Christos 2, Boletis N. John 3, Diamandopoulos
More informationHemizygous Fabry disease associated with IgA nephropathy: A case report
1 Hemizygous Fabry disease associated with IgA nephropathy: A case report Fabry disease and IgA nephropathy Homare Shimohata 1, 3, Keigyou Yoh 1, Kenji Takada 2, Hiroaki Tanaka 2, Joichi Usui 1, Kouichi
More informationHeterozygous Fabry Disease Females Are Not Just Carriers, But Suffer From
Heterozygous Fabry Disease Females Are Not Just Carriers, But Suffer From Significant Burden of Disease And Impaired Quality of Life Raymond Wang, M.D. Children s Hospital of Orange County Division of
More informationStage I: Rule-Out Dashboard
Stage I: Rule-Out Dashboard GENE/GENE PANEL: GLA DISORDER: Fabry disease HGNC ID: 4296 OMIM ID: 301500 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic
More informationFabry Disease in Latin America: Data from the Fabry Registry
JIMD Reports DOI 10.1007/8904_2012_165 RESEARCH REPORT Fabry Disease in Latin America: Data from the Fabry Registry J. Villalobos J.M. Politei A.M. Martins G. Cabrera H. Amartino R. Lemay S. Ospina S.
More informationMedication Policy Manual. Topic: Fabrazyme, agalsidase beta Date of Origin: February 17, 2015
Medication Policy Manual Policy No: dru391 Topic: Fabrazyme, agalsidase beta Date of Origin: February 17, 2015 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: July
More informationA Unique Disease Uniquely Experienced
A Unique Disease Uniquely Experienced Understanding Fabry disease a serious, progressive disorder with complex pathology 1 Fabry disease is an X-linked lysosomal storage disorder. 1 Caused by a deficiency
More informationFabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy Raphael Schiffmann, National Institute of Neurological Disorders and Stroke
More informationFabry nephropathy: a review how can we optimize the management of Fabry nephropathy?
Waldek and Feriozzi BMC Nephrology 2014, 15:72 REVIEW Open Access Fabry nephropathy: a review how can we optimize the management of Fabry nephropathy? Stephen Waldek 1* and Sandro Feriozzi 2 Abstract Fabry
More informationSustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Therapy in Patients with Fabry Disease
Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Therapy in Patients with Fabry Disease Dominique P. Germain,* Stephen Waldek, Maryam Banikazemi, David A. Bushinsky, Joel Charrow,
More informationHeart disease. Other symptoms too? FABRY DISEASE IN PATIENTS WITH UNEXPLAINED HEART CONDITIONS
Heart disease Other symptoms too? FABRY DISEASE IN PATIENTS WITH UNEXPLAINED HEART CONDITIONS You have been given this brochure because your heart condition may be linked to Fabry disease, which is a rare,
More informationAnderson Fabry disease: Ten year outcome of enzyme replacement therapy in a renal transplant patient
CASE REPORT Port J Nephrol Hypert 2016; 30(2): 000-000 Advance Access publication 24 April 2016 Anderson Fabry disease: Ten year outcome of enzyme replacement therapy in a renal transplant patient Department
More informationFabry disease: An underrecognized cause of proteinuria
http://www.kidney-international.org & 2008 International Society of Nephrology the renal consult Fabry disease: An underrecognized cause of proteinuria FC Fervenza 1, R Torra 2 and DJ Lager 3 1 Department
More informationCardiomyopathy in Fabry s disease
Cardiomyopathy in Fabry s disease Herzinsuffizienzlunch Basel, 11.09.2018 Christiane Gruner Kardiologie, UniversitätsSpital Zürich Content Background / epidemiology Differential diagnosis Clinical presentations
More informationYin-Hsiu Chien, 1 Ni-Chung Lee, 1 Shu-Chuan Chiang, 1 Robert J Desnick, 2 and Wuh-Liang Hwu 1
Fabry Disease: Incidence of the Common Later-Onset α-galactosidase A IVS4+919G A Mutation in Taiwanese Newborns Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations Yin-Hsiu
More informationClinical benefit of enzyme replacement therapy in Fabry disease
original article http://www.kidney-international.org & 2006 International Society of Nephrology Clinical benefit of enzyme replacement therapy in Fabry disease F Breunig 1, F Weidemann 2, J Strotmann 2,
More informationNEPHROPATHOLOGY- ELECTRON MICROSCOPY SEMINAR: CASE 2
NEPHROPATHOLOGY- ELECTRON MICROSCOPY SEMINAR: CASE 2 ABSTRACT We present the case of a 32 years old woman with nephrotic range proteinuria. The proteinuria was first detected on a routine medical checkup,
More informationGalafold (migalastat) or Fabrazyme (agalsidase beta) Prior Authorization Criteria:
Request for Prior Authorization for Fabry Disease Medications Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Galafold (migalastat) or Fabrazyme (agalsidase
More informationPAEDIATRIC MANAGEMENT KDIGO. Uma Ramaswami FRCPCH, MD Royal Free London NHS Foundation Trust
PAEDIATRIC MANAGEMENT Uma Ramaswami FRCPCH, MD Royal Free London NHS Foundation Trust Disclosure of Interests UR has received travel grants and lecture fees from Shire HGT, Amicus and Genzyme; and advisory
More informationProgressive nephropathy is one of the main features of
CJASN epress. Published on January 7, 2010 as doi: 10.2215/CJN.08091109 Assessment of Renal Pathology and Dysfunction in Children with Fabry Disease Uma Ramaswami,* Behzad Najafian, Arrigo Schieppati,
More informationMosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease Michael Mauer 1,2, Emily Glynn 3, Einar Svarstad 4,5, Camilla Tøndel 5,6, Marie-Claire Gubler 7, Michael West
More informationLong-Term Effect of Antibodies against Infused Alpha- Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)gb3 Reduction and Treatment Outcome
Long-Term Effect of Antibodies against Infused Alpha- Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)gb3 Reduction and Treatment Outcome Saskia M. Rombach 1, Johannes M. F. G. Aerts 2, Ben
More informationFabry RADAR 2007 The Fabry Registry Aggregate Data Annual Report
Fabry RADAR 2007 The Fabry Registry Aggregate Data Annual Report A program supported by Genzyme Fabr/GL/P341/05/07 2007 Genzyme Corporation. All rights reserved. Table of Contents I. II. III. IV. V. VI.
More informationAssessment report. for
Assessment report for FABRAZYME agalsidase beta Assessment report on the shortage of Fabrazyme Overview of Shortage Period: Spontaneous Reports from June 2009 through 15 September and Registry Data from
More informationFabry disease: Kidney involvement and enzyme replacement therapy
Kidney International, Vol. 65 (2004), pp. 744 753 Fabry disease: Kidney involvement and enzyme replacement therapy Principal discussant: KOSTAS C. SIAMOPOULOS Division of Nephrology; Department of Medicine,
More informationFabry disease is a rare X-linked metabolic disorder caused by
ARTICLE Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry Torquil Watt, MD 1, Alessandro P. Burlina, MD 2, Chiara Cazzorla,
More informationPedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females
Pedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females B.E. Gutiérrez-Amavizca 1,2, R. Orozco-Castellanos 3,4, J. R. Padilla-Gutiérrez 5,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationThis presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business,
American Society of Nephrology (ASN) Migalastat Monotherapy Phase 3 Data N November b 15 15, 2014 Safe Harbor This presentation contains forward looking statements within the meaning of the Private Securities
More informationEfficacy and safety of enzyme-replacementtherapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
Tsuboi and Yamamoto BMC Pharmacology and Toxicology (2017) 18:43 DOI 10.1186/s40360-017-0152-7 RESEARCH ARTICLE Open Access Efficacy and safety of enzyme-replacementtherapy with agalsidase alfa in 36 treatment-naïve
More informationAntiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-
Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase- Hindia Tahir, Leslie L. Jackson, and David G. Warnock
More informationCase Report Early Renal Involvement in a Girl with Classic Fabry Disease
Hindawi Case Reports in Nephrology Volume 2017, Article ID 9543079, 4 pages https://doi.org/10.1155/2017/9543079 Case Report Early Renal Involvement in a Girl with Classic Fabry Disease Fernando Perretta,
More informationFabry Disease: A rare condition emerging from the darkness
Fabry Disease: A rare condition emerging from the darkness Running Title: Fabry Disease: A rare condition emerging from the darkness Professor Perry Elliott MBBS; MD; FRCP; FESC; FACC Chair of Cardiovascular
More informationFabry meets Markov: evaluating biochemistry, disease course and costs in support of health care policy Rombach, S.M.
UvA-DARE (Digital Academic Repository) Fabry meets Markov: evaluating biochemistry, disease course and costs in support of health care policy Rombach, S.M. Link to publication Citation for published version
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationClinical features and diagnosis of Fabry disease
Clinical features and diagnosis of Fabry disease Monique E Cho, MD Jeffrey B Kopp, MD UpToDate performs a continuous review of over 375 journals and other resources. Updates are added as important new
More informationWhat is a rare disease?
What is a rare disease? A disease or disorder is defined as rare in Europe when it affects less than 1 in 2000 citizens (Orphan Drug Regulation 141/2000) Rare diseases may affect 30 million European Union
More informationMorbus Fabry. Bruno Conti Rossini. Sostituto primario Ospedale Regionale di Locarno
Morbus Fabry Bruno Conti Rossini Sostituto primario Ospedale Regionale di Locarno Problem: Anesthesiologic ambulatory preanesthetic consultation for peripartal epidural anesthesia the call: we have a pregnant
More informationFabry disease is an X-linked lysosomal storage disorder,
Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events Natural History Data From the Fabry Registry Katherine Sims, MD; Juan Politei, MD; Maryam Banikazemi,
More informationMonitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate
Nephrol Dial Transplant (2010) 25: 1507 1513 doi: 10.1093/ndt/gfp658 Advance Access publication 27 December 2009 Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based
More information2 nd Latin American Fabry Round Table
2 nd Latin American Fabry Round Table FABRY DISEASE AND THE KIDNEY KIDNEY PATHOPHYSIOLOGIC PATHWAYS OF DISEASE REVISITED FOCUS ON THE PODOCYTE AND OTHER ISSUES HERNÁN TRIMARCHI CHIEF NEPHROLOGY AND RENAL
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationScreening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation Ana Baptista, Pedro Magalhães, Sílvia Leão, Sofia Carvalho, Pedro Mateus, Ilídio Moreira Centro Hospitalar
More informationWhat s hiding behind IgA nephropathy?
What s hiding behind IgA nephropathy? Bauerova L. Department of Pathology, the First Faculty of Medicine and General Hospital, Charles University Prague (nephropathology training: Department of Clinical
More informationCase Report Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease
Case Reports in Nephrology Volume 2015, Article ID 257628, 4 pages http://dx.doi.org/10.1155/2015/257628 Case Report Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationFabry disease: a review of current management strategies
Fabry disease: a review of current management strategies A. MEHTA 1, M. BECK 2, F. EYSKENS 3, C. FELICIANI 4, I. KANTOLA 5, U. RAMASWAMI 6, A. ROLFS 7, A. RIVERA 8, S. WALDEK 9, D.P. GERMAIN 10 1 Lysosomal
More informationFabry Registry Annual Report 2010
Fabry Registry Annual Report 2010 (This report covers data collected through 31 December 2009) FMRB-0009-01 Table of Contents I. Foreword...2 II. Introduction...3 III. SELECTED CURRENT DATA...4 Women
More informationFabry Disease Glossary
Fabry Disease Glossary A Acroparesthesia: A tingling sensation in the hands and feet. Angiokeratoma: Localized collection of thin-walled blood vessels covered by a cap of warty material. Also described
More informationPatients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch
atients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch Frank Weidemann,* Johannes Krämer,* Thomas Duning, Malte Lenders, Sima Canaan- Kühl, Alice Krebs, Hans
More informationFigure S1. LVMi Change over 18 months on Migalastat and ERT
Figure S1. LVMi Change over 18 months on Migalastat and ERT Mean change to month 18 in mitt patients (all randomized, treated patients with amenable mutations); LVMi decreased significantly (95% CI does
More informationImpact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationGALAFOLD (migalastat) oral capsule
GALAFOLD (migalastat) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPrevalence of symptoms in female Fabry disease patients: a case-control survey
J Inherit Metab Dis (2012) 35:891 898 DOI 10.1007/s10545-011-9447-9 ORIGINAL ARTICLE Prevalence of symptoms in female Fabry disease patients: a case-control survey Machtelt G. Bouwman & Saskia M. Rombach
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationPhase 3 investigation of lucerastat for patients with Fabry disease. Investor Webcast May 2018
Phase 3 investigation of lucerastat for patients with Fabry disease Investor Webcast May 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationEnzyme replacement therapy in Fabry disease, towards individualized treatment Arends, M.
UvA-DARE (Digital Academic Repository) Enzyme replacement therapy in Fabry disease, towards individualized treatment Arends, M. Link to publication Citation for published version (APA): Arends, M. (2017).
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationS2 Protein augmentation therapies for inherited disorders 1
Disease category Disorder S2 Protein augmentation therapies for inherited 1 Augmented protein 2 Source of therapeutic protein / peptide Outcome References 3 Membrane transport Coagulation Cystic fibrosis
More informationMonitoring the 3-Year Efficacy of Enzyme Replacement Therapy in Fabry Disease by Repeated Skin Biopsies
See related Commentary on page iv Monitoring the 3-Year Efficacy of Enzyme Replacement Therapy in Fabry Disease by Repeated Skin Biopsies Beth L. Thurberg, H. Randolph Byers,w 1 Scott R. Granter,z 1 Robert
More informationGlobotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy
Kidney International, Vol. 62 (2002), pp. 1933 1946 GENETIC DISORDERS DEVELOPMENT Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationInitially Nondiagnosed Fabry s Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis
Published online: May 4, 2013 1664 5510/13/0031 0051$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationFabry Disease: A complex multisystem disorder
Fabry Disease: A complex multisystem disorder Dr. Bertram Henderson Division of Clinical Genetics, UFS/FPA 1 2 Speaker Disclosure The speaker has received sponsorship from Sanofi Genzyme to attend workshops,
More informationREVIEW ARTICLE NEWER BIOMARKERS IN EARLY DIABETIC NEPHROPATHY
JCD REVIEW ARTICLE NEWER BIOMARKERS IN EARLY DIABETIC NEPHROPATHY SAPTARSHI MUKHOPADHYAY* *FACULTY (DEPARTMENT OF MEDICINE), B R SINGH HOSPITAL (EASTERN RAILWAY), KOLKATA. INTRODUCTION renal disease. It
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationTesting for Fabry Disease. What You Need to Know
Testing for Fabry Disease What You Need to Know Identification of One Family Member Can Enable Earlier Screening for Others A woman with Fabry disease may have inherited it from either her mother or her
More informationManagement of Fabry Disease with Agalsidase Treatment
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management of Fabry Disease with Agalsidase Treatment Guillem
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationLong-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment Frank Weidemann, MD*; Markus Niemann*; Frank Breunig, MD; Sebastian Herrmann;
More informationFabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.
Fabry Disease X-linked genetic, multi-organ disorder Fabry disease screening program in Hypertrophic p Cardiomyopathy: y preliminary results. Globotriaosylceramide, GL3 Brain -galactosidase A Eyes Lactosylceramide
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationAnderson-Fabry disease: recommendations for its diagnosis, management and treatment in South Africa, 2014
Anderson-Fabry disease: recommendations for its diagnosis, management and treatment in South Africa, 2014 Bhengu L, MBChB, FCP(SA), CertMedGenetics(SA), Medical Geneticist, University of the Witwatersrand
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationInborn Errors of Metabolism. Landi Lombard Endocrinologist Kuilsrivier
Inborn Errors of Metabolism Landi Lombard Endocrinologist Kuilsrivier Classification of Inborn Errors of Metabolism Amino acid disorders eg Phenylketonuria Organic acidemias eg Maple syrup urine disease
More informationSummary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationShort-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
J Korean Med Sci 2008; 23: 243-50 ISSN 1011-8934 DOI: 10.3346/jkms.2008.23.2.243 Copyright The Korean Academy of Medical Sciences Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with
More informationQuestioning the Pathogenic Role of the GLA p.ala143thr Mutation in Fabry Disease: Implications for Screening Studies and ERT
JIMD Reports DOI 10.1007/8904_2012_167 RESEARCH REPORT Questioning the Pathogenic Role of the GLA p.ala143thr Mutation in Fabry Disease: Implications for Screening Studies and ERT W. Terryn R. Vanholder
More informationReview Article Artigo de Revisão
Review Article Artigo de Revisão Renal involvement in Fabry disease Acometimento renal na doença de Fabry Authors Hugo Abensur 1 Marlene Antônia dos Reis 2 1 Universidade de São Paulo. 2 Universidade Federal
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More information